| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 McGill Pharmacoepidemiology Research Unit, McGill University Health Centre, 2 Depts of Epidemiology and Biostatistics and of Medicine, McGill University, Montreal, and 3 Ottawa Health Research Institute, University of Ottawa, Ottawa, ON, Canada.
CORRESPONDENCE: S. Suissa, Division of Clinical Epidemiology, Royal Victoria Hospital, 687 Pine avenue west, Ross 4.29, Montreal, Québec H3A 1A1, Canada, Fax 1 5148431493. E-mail: samy.suissa{at}clinepi.mcgill.ca
Keywords: Biases, chronic obstructive pulmonary disease, data analysis, drug effectiveness, inhaled corticosteroids, study design methods
Received: August 1, 2007
Accepted January 10, 2008
The recent Towards a Revolution in COPD Health (TORCH) randomised trial replicated the findings of previous trials in chronic obstructive pulmonary disease (COPD) on the apparent effectiveness of inhaled corticosteroids (ICS) in reducing exacerbation rates, but not so for mortality.
In the present article, the authors review methodological issues in the TORCH and previous trials, such as patients already receiving ICS before randomisation and the absence of follow-up after study drug discontinuation, using data from two trials.
First, among previous ICS users in the Canadian Optimal Therapy of COPD Trial, the hazard ratio of the first exacerbation with ICS relative to bronchodilators was 0.71 (95% confidence interval (CI) 0.53–0.96), while among those not using ICS prior to randomisation, it was 1.11 (95% CI 0.69–1.79). Secondly, the rate ratio of exacerbations with ICS was 0.78 (95% CI 0.61–0.99) prior to drug discontinuation during follow-up and 1.23 (95% CI 0.78–1.95) thereafter. Finally, a 2x2 factorial analysis of the TORCH data found a rate ratio of mortality for the salmeterol component to be 0.83 (95% CI 0.74–0.95), while for the fluticasone component it was 1.00 (95% CI 0.89–1.13).
In conclusion, after proper consideration of the various methodological shortcomings in the design and analysis of randomised trials, the effectiveness of inhaled corticosteroids in treating chronic obstructive pulmonary disease remains doubtful, while the benefit observed with combination therapy may be due exclusively to the beneficial effects of the long-acting bronchodilator alone.
This article has been cited by other articles:
|
|
 |
|
  P. J. Barnes Future Treatments for Chronic Obstructive Pulmonary Disease and Its Comorbidities Proceedings of the ATS, December 1, 2008; 5(8): 857 - 864. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Barnes Emerging Pharmacotherapies for COPD Chest, December 1, 2008; 134(6): 1278 - 1286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Suissa Methodologic Shortcomings of the INSPIRE Randomized Trial Am. J. Respir. Crit. Care Med., November 15, 2008; 178(10): 1090 - 1091. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Suissa Exacerbations and intent-to-treat analyses in randomised trials Eur. Respir. J., October 1, 2008; 32(4): 1117 - 1118. [Full Text] [PDF]
|
|
|
|
|
|
S. F. Lanes and M. Jara The INSPIRE Study: Influence of Prior Use and Discontinuation of Inhaled Corticosteroids Am. J. Respir. Crit. Care Med., September 1, 2008; 178(5): 543 - 544. [Full Text] [PDF]
|
|
|
|
|
|
S. Suissa Medications to Modify Lung Function Decline in Chronic Obstructive Pulmonary Disease: Some Hopeful Signs Am. J. Respir. Crit. Care Med., August 15, 2008; 178(4): 322 - 323. [Full Text] [PDF]
|
|
|
|
|
|
B. R. Celli, N. E. Thomas, J. A. Anderson, G. T. Ferguson, C. R. Jenkins, P. W. Jones, J. Vestbo, K. Knobil, J. C. Yates, and P. M. A. Calverley Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease: Results from the TORCH Study Am. J. Respir. Crit. Care Med., August 15, 2008; 178(4): 332 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Cooper and M. Decramer Inhaled steroids and COPD Eur. Respir. J., August 1, 2008; 32(2): 523 - 524. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
